Kurs
+9,16%
Kurs
+9,16%
Open
0,40
High
0,41
Low
0,37
Close
0,41
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
Tid* | ||
2025-08-29 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-28 | N/A | Årsstämma |
2025-03-18 | 21:30 | Bokslutskommuniké 2024 |
2025-01-07 | N/A | Extra Bolagsstämma 2025 |
2024-08-26 | - | Kvartalsrapport 2024-Q2 |
2024-05-27 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
2024-05-24 | - | Årsstämma |
2024-03-13 | - | Bokslutskommuniké 2023 |
2023-11-22 | - | Extra Bolagsstämma 2023 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-30 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
2023-05-26 | - | Årsstämma |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | 15-10 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-06-03 | - | Årsstämma |
2022-06-03 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
2022-03-29 | - | Bokslutskommuniké 2021 |
2022-02-04 | - | Extra Bolagsstämma 2022 |
2021-11-03 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-05-25 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
2021-05-21 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-23 | - | Bokslutskommuniké 2020 |
2020-11-03 | - | Kvartalsrapport 2020-Q3 |
2020-08-18 | - | Kvartalsrapport 2020-Q2 |
2020-07-01 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
2020-06-30 | - | Årsstämma |
2020-06-16 | - | Extra Bolagsstämma 2020 |
2020-05-12 | - | Kvartalsrapport 2020-Q1 |
2020-02-25 | - | Bokslutskommuniké 2019 |
Beskrivning
Land | Norge |
---|---|
Lista | OAX Equities |
Sektor | Hälsovård |
Industri | Medicinteknik |
2024-12-12 20:00:06
Oslo, 12 December 2024: Observe Medical ASA (the "Company") has been informed
that Rune Nystad, CDO and primary insider in the Company, has sold
1,144,962 shares in the Company to his wholly owned investment company US
Holding AS as part of a reorganization of his shareholding.
Following this, 1,662,483 of the shares in Observe Medical ASA is still
controlled by Rune Nystad.
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.